Ramon Luengo-Fernandez MA, MSc, DPhil
- Cohort Study
- Quality of Life
- Luengo-Fernandez R, Silver LE, Gutnikov SA, Gray AM, and Rothwell PM (2013) Hospitalization Resource Use and Costs Before and After TIA and Stroke: Results from a Population-Based Cohort Study (OXVASC) Value in Health, Epub ahead of print Jan 2013.
- Paul Nicola LM, Koton Silvia, Simoni Michela, Geraghty Olivia C, Luengo-Fernandez Ramon, and Rothwell Peter M (2013) Feasibility, safety and cost of outpatient management of acute minor ischaemic stroke: a population-based study. J Neurol Neurosurg Psychiatry, 84(3):356-61.
- Leal J, Luengo-Fernandez R, and Gray AM (2012) Economic Costs In: Nicholas M, Townsend N, Scarborough P, Rayner M et al. European Cardiovascular Disease Statistics 2012, European Heart Network, Brussels, European Society of Cardiology, Sophia Antipolis.
- Luengo-Fernandez Ramon, Gray Alastair M, Rothwell Peter M, and on behalf of the Oxford Vascular Study (2012) A Population-Based Study of Hospital Care Costs During 5 Years After Transient Ischemic Attack and Stroke. Stroke, 43(12):3343-3351.
- Luengo-Fernandez R, Leal J, and Gray A M (2012) UK research expenditure on dementia, heart disease, stroke and cancer: are levels of spending related to disease burden? Eur J Neurol, 19(1):149-54.
|Tel||+44 (0)1865 289 264|
|Fax||+44 (0)1865 289 271|
Ramón Luengo-Fernandez joined the Health Economics Research Centre in January 2004 having completed his MSc in Health Economics at the University of York in 2003. In October 2005, Ramón took up a Researcher Development award from the UK Department of Health. As part of this award, in June 2009, Ramón successfully completed a DPhil at the University of Oxford on the healthcare costs and health outcomes associated with stroke. Shortly after, Ramón was awarded an ESRC/MRC/NIHR Early career fellowship in economics of health to publish and further develop the work undertaken as part of his DPhil thesis. During his time in HERC Ramon has also been involved in a number of other projects evaluating the economic burden of cardiovascular diseases, stroke, and dementia/Alzheimer’s disease in the UK and in the European Union.